VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AYTU
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AYTUAytu BioPharma, Inc.
$2.66$22M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksAYTUCash Flow

Aytu BioPharma, Inc. (AYTU) Cash Flow Statement

20Y historyFree accessUpdated daily

Free cash flow remains persistently negative, evidenced by a -33.7% FCF margin in 2026Q3, indicating that the firm continues to burn cash despite minimal capital expenditures.

Income StatementBalance SheetCash FlowRatios

AYTU Cash Flow Statement

Annual statement

AYTU Cash Flow Statement

Aytu BioPharma, Inc. (AYTU) cash flow statement — 20-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMJun'26Jun'25Jun'24Jun'23Jun'22Jun'21Jun'20Jun'19Jun'18Jun'17Jun'16Jun'15Aug'14Aug'13Aug'12Aug'11Aug'10Aug'09Aug'08Aug'07
Cash from Operations3.62M3.28M-1.94M-1.39M-5.13M-28.82M-25.96M-28.37M-13.83M-15.94M-13.83M-10.66M-6.63M-5.5M-37.7K-37.85K-64.82K-43.38K-46.63K-44.8K-27.92K
Operating CF Margin %-5.7%-2.92%-2.13%-4.78%-29.82%-39.56%-102.68%-188.94%-435.53%-429.28%-415.91%-2534.25%-9336.59%-2154.51%-2162.8%---2664.63%--
Operating CF Growth %174.41%269.39%-39.55%72.94%82.21%-11.01%8.49%-105.14%13.23%-15.26%-29.77%-60.64%-20.58%-14492.52%0.38%41.61%-49.44%6.98%-4.09%-60.48%-
Net Income-20.1M-14.25M-13.56M-15.84M-17.05M-108.78M-58.29M-13.62M-27.13M-10.19M-22.51M-28.18M-7.72M-5.58M-57.32K-59.67K-136.8K-60.27K-58.89K-57.17K-48.95K
Depreciation & Amortization4.25M3.93M5.38M6.72M8.81M10.15M9.2M5.71M2.73M2.59M4.36M874.79K118.2K97.48K4.94K6.15K6.76K9.19K8.28K7.51K6.42K
Stock-Based Compensation748K691K576K2.37M6.05M5.25M3.57M1.08M1.02M348.51K2.5M902.95K1.02M500K317K060K0000
Deferred Taxes0000000573.53K-80.78K-1.94M1.62M13.55M-23.91K-813.7K00136.8K0000
Other Non-Cash Items12.87M7.08M11.4M10.02M2.86M75.42M17.87M-9.51M9.84M-6.03M1.23M403.78K121.98K35.58K8.18K7.34K-132.55K2.58K4.47K4.54K9.4K
Working Capital Changes5.86M5.83M-5.73M-4.66M-5.8M-10.86M1.68M-12.61M-210.2K-718.81K-1.04M1.79M-145.02K257.68K6.49K8.34K9715.13K-4873165.22K
Change in Receivables12.89M8.38M-7.63M5.2M-7.15M6.53M1.54M-3.56M-1.16M-50.74K-355.03K-5.37K-157.06K-6.91K0000000
Change in Inventory1.69M2.39M382K-4.82M-3.61M1.3M2.79M-6.95M-101.1K-26.75K195.43K-485.26K-39.44K-10.45K0000000
Change in Payables-3.83M-2.32M287K-2.08M2.38M-7.68M-3.25M-1.38M134.78K-109.71K493.22K1.62M547.31K421.87K0000000
Cash from Investing-29K-29K-2.56M-329K-117K-3.25M-2.78M-5.66M-1.06M-484.29K-3.53M-5.3M-1M-9.3K-338.92K00-6.58K-7.47K-7.47K0
Capital Expenditures-29K-29K-228K-329K0000-59.85K-74.71K-111.61K-2.25M0-9.3K-8.92K00-6.58K0-7.47K0
CapEx % of Revenue0.05%0.05%0.34%0.5%----0.82%2.04%3.46%87.92%-15.78%509.71%------
Acquisitions0000-5K-3.18M-481K188.23K-505.02K-7.38K-4.04M-3.05M-1M00000000
Investments---------------------
Other Investing00-2.33M0-112K-70K-2.3M-5.84M-497.11K-402.2K613.31K2K-4.89K0-330K00-6.58K-7.47K-7.47K0
Cash from Financing-10.73M-7.9M15.44M-1.26M8.87M1.53M30.31M71.07M19.08M22.66M10.19M16.66M12.35M5.24M39.46K33.97K67.27K37.88K22.6K66.55K2.4K
Debt Issued (Net)-10.19M-7.9M6.67M-1.89M-2.35M-5.22M-3.74M-16.25M5M005.17M021.48K31.46K15.75K23.77K22.98K6.5K6.8K2.4K
Equity Issued (Net)0014.84M3.47M15.57M11.69M40.15M131.46M024.74M9.34M12.72M5M17.7K8K18.21K43.5K14.9K16.1K59.75K0
Dividends Paid000000000000000000000
Share Repurchases000000000000000000000
Other Financing-539K0-6.07M-2.84M-4.36M-4.94M-6.09M-44.14M14.08M-2.08M845.19K-1.23M7.35M00000000
Net Change in Cash-7.14M-4.64M10.95M-2.98M3.63M-30.54M1.57M37.04M4.18M6.23M-7.18M701.13K4.71M-274.05K1.75K-3.88K2.45K-12.07K-24.03K14.29K-25.52K
Free Cash Flow3.6M3.25M-5.17M-1.72M-5.13M-28.82M-25.96M-28.37M-13.89M-16.02M-13.94M-12.91M-6.63M-5.51M-46.62K-37.85K-64.82K-49.95K-46.63K-52.27K-27.92K
FCF Margin %6.14%5.65%-7.78%-2.63%-4.78%-29.82%-39.56%-102.68%-189.76%-437.57%-432.74%-503.83%-2534.25%-9352.37%-2664.23%-2162.8%---2664.63%--
FCF Growth %346.74%162.96%-200.82%66.52%82.21%-11.01%8.49%-104.26%13.26%-14.88%-7.98%-94.6%-20.38%-11720.65%-23.18%41.61%-29.76%-7.12%10.78%-87.22%-
FCF per Share0.190.26-0.82-0.31-1.54-19.61-30.91-123.36-356.44-4812.21-119156.07-593169.47-473872.43-612362.22-5828.00-4731.13-8102.25-8325.17-9326.20-10453.00-
FCF Conversion (FCF/Net Income)-0.18x-0.23x0.14x0.09x0.30x0.26x0.45x2.08x0.29x1.56x0.61x0.38x0.86x0.99x0.66x0.63x0.47x0.72x0.79x0.78x0.57x
Interest Paid1.32M1.79M2.82M4.04M3.81M3.15M1.25M00000000000000
Taxes Paid71K211K1.42M1.61M00000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Persistent operating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Earnings Quality Remains Highly Disconnected

According to quarterly financial data, AYTU exhibits a persistent disconnect between net income and operating cash flow, evidenced by a volatile OCF/NI ratio that swung from 3.69 in 2025Q2 to -1.62 in 2025Q3, suggesting that reported earnings are frequently decoupled from actual cash generation.

The frequent divergence between net income and cash flow suggests that non-cash items and working capital fluctuations are masking the underlying cash-generating capacity of the business. Investors should monitor whether this volatility is a result of aggressive revenue recognition or simply the inherent lumpiness of pharmaceutical rebate true-ups.

Free Cash Flow Trajectory Remains Negative

As reported in recent filings, AYTU's free cash flow trajectory remains firmly in negative territory, with a -33.7% FCF margin in 2026Q3, indicating that the company continues to consume cash rather than generate it despite its specialized ADHD product portfolio and high-margin manufacturing capabilities.

The inability to sustain positive free cash flow suggests that the current cost structure is misaligned with the company's revenue scale. Without a significant shift in prescription volume or a reduction in operating expenses, the company may continue to face liquidity pressure that necessitates external financing.

Working Capital Volatility Obscures Performance

Based on the provided cash flow statements, working capital changes have been a primary driver of cash flow volatility, with a significant $9.8M outflow in 2025Q3 followed by a $4.0M inflow in 2026Q2, highlighting the sensitivity of the company's cash position to inventory and receivable management.

The erratic nature of these working capital swings suggests that the company's cash flow is highly susceptible to channel inventory management and the timing of PBM payments. This volatility makes it difficult to forecast the company's true cash burn rate and warrants further investigation into the underlying collection cycles.

Hidden Cash Pressures Beyond Operations

Analysis of the cash flow statement reveals that while capital expenditures remain minimal, the company's reliance on stock-based compensation and non-cash adjustments, as seen in the 2024Q2 period with $707K in SBC, may be masking the true economic cost of maintaining its current sales force.

The reliance on non-cash compensation to retain talent in a competitive specialty pharma market may be understating the true operating expense burden. Investors should consider whether these adjustments are sustainable or if they represent a long-term dilution risk that is not fully captured in the headline cash flow metrics.

AYTU — Frequently Asked Questions

Quick answers to the most common questions about buying AYTU stock.

How much cash does Aytu BioPharma, Inc. (AYTU) generate from operations?

Aytu BioPharma, Inc. (AYTU) generated $3.3M in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.

What is Aytu BioPharma, Inc.'s free cash flow?

Aytu BioPharma, Inc. (AYTU) generated $3.3M in free cash flow in 2026. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Aytu BioPharma, Inc.'s capital expenditure (CapEx)?

Aytu BioPharma, Inc. (AYTU) spent $0.0M on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.